Opportunity Information: Apply for RFA MD 18 009
Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) is a National Institutes of Health (NIH) funding opportunity aimed at supporting U.S. small businesses that want to turn practical health innovations into real-world, commercialized products or services. The program uses the SBIR mechanism, meaning it is specifically designed to help small business concerns (SBCs) move an idea from early development through later-stage research and development, with an emphasis on innovations that can realistically make it into the marketplace and be used at scale.
The central purpose of the opportunity is to improve minority health and reduce or eliminate health disparities affecting NIH-defined health disparity population groups. In practice, that means the proposed work should directly address differences in health outcomes, access, or quality of care that disproportionately burden certain populations. The announcement is intentionally broad about the type of solution that can be proposed. Applicants can focus on developing a product, process, or service, as long as it has a credible pathway toward commercialization and is positioned to have meaningful impact on disparity-related health challenges.
A key expectation is that the technology or approach should be effective, affordable, and culturally acceptable. That combination is important because disparity-focused innovations often fail when they are too expensive to deploy, require infrastructure that underserved settings do not have, or do not fit the cultural, language, or community context of the people they are meant to help. Competitive projects under this FOA would typically show that the applicant has thought through real-world adoption issues, such as usability, trust, language access, workflow fit in low-resource clinics, and the practical costs of implementation and maintenance.
The FOA uses the R43/R44 SBIR grant structure. R43 generally corresponds to Phase I work, which often focuses on feasibility, proof of concept, and early prototype development. R44 generally corresponds to Phase II work, which is typically more substantial R and D to refine the technology and generate stronger evidence supporting performance, usability, or effectiveness. The "Clinical Trial Optional" designation means a clinical trial is not required for every project, but may be included if it makes sense for the proposed technology and stage of development. Applicants considering a clinical trial would need to ensure their plans match NIH expectations for human subjects protections, study design rigor, and appropriate outcome measures, while keeping the project aligned with commercialization goals.
Eligibility is limited to U.S. small businesses. Foreign institutions are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply as part of the application. However, the FOA notes that foreign components may be allowed under the NIH Grants Policy Statement definition, which generally refers to specific, well-justified elements of the project that must be performed outside the United States. Even when allowed, foreign components are usually scrutinized closely for necessity and value, and they do not change the rule that the applicant organization itself must be a U.S. SBC.
From the provided source data, this is a discretionary grant opportunity under the health funding category, listed under CFDA number 93.307 and administered by NIH. The Funding Opportunity Number is RFA-MD-18-009, and the title emphasizes innovations for healthy living with a focus on minority health and eliminating disparities. The record shows an original closing date of 2018-10-01 and a creation date of 2018-08-01, indicating it was a time-limited solicitation released in 2018. The excerpt does not specify an award ceiling or the expected number of awards, so applicants would normally need to review the full FOA text for budget caps, project period limits, and detailed review criteria.
Overall, the opportunity is best understood as an NIH SBIR commercialization-focused solicitation for small businesses developing practical, scalable solutions that can measurably improve health outcomes and reduce inequities for populations experiencing health disparities. The strongest applications would typically combine a clear disparity-focused public health need, a technology that can be deployed in real settings at reasonable cost, a plan that accounts for cultural and community fit, and a credible commercialization strategy showing how the innovation will reach the people who need it.Apply for RFA MD 18 009
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.307.
- This funding opportunity was created on 2018-08-01.
- Applicants must submit their applications by 2018-10-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the "Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)" opportunity?
This is a National Institutes of Health (NIH) Small Business Innovation Research (SBIR) funding opportunity designed to support U.S. small businesses developing practical health innovations that can be moved toward real-world use and commercialization. The focus is on innovations that improve minority health and reduce or eliminate health disparities affecting NIH-defined health disparity population groups.
What is the main goal of this funding opportunity?
The central goal is to support development of products, processes, or services that can measurably improve minority health and reduce or eliminate health disparities. The opportunity emphasizes solutions that are positioned to be used at scale in real settings and that have a credible path to commercialization.
Who is this grant intended for?
It is intended for U.S. small business concerns (SBCs) applying through the NIH SBIR mechanism (R43/R44). The applicant organization must be a U.S. small business.
Are non-U.S. (foreign) organizations eligible to apply?
No. Foreign institutions are not eligible to apply. In addition, non-U.S. components of U.S. organizations are not eligible to apply as part of the application.
Are any foreign activities allowed under this opportunity?
The opportunity notes that foreign components may be allowed under the NIH Grants Policy Statement definition. These are typically limited, specifically justified elements of the project that must be performed outside the United States. Allowability of foreign components does not change the requirement that the applicant must be a U.S. small business concern.
What types of projects or solutions can be proposed?
The announcement is broad about solution types. Applicants may propose a product, process, or service, as long as it directly addresses minority health and/or health disparities and has a realistic pathway toward commercialization and scale.
What does it mean to focus on "health disparities" in this program?
In this context, health disparities refer to differences in health outcomes, access, or quality of care that disproportionately affect NIH-defined health disparity population groups. Proposed work should be directly aimed at reducing or eliminating these inequities.
What is meant by "commercialization-focused" in the SBIR context?
It means the project should move beyond an idea alone and show a credible route to a product or service that can enter the marketplace and be used in real-world conditions. The emphasis is on practical innovations that can realistically be deployed and sustained at scale.
What does R43/R44 mean?
R43 and R44 refer to NIH SBIR grant phases. R43 generally aligns with Phase I activities (feasibility, proof of concept, early prototype development). R44 generally aligns with Phase II activities (more substantial research and development to refine the technology and generate stronger supporting evidence, such as performance, usability, or effectiveness).
Is a clinical trial required?
No. The opportunity is labeled "Clinical Trial Optional," meaning a clinical trial is not required for every project. However, a clinical trial may be included if it is appropriate for the technology and the stage of development.
If a clinical trial is included, what expectations apply?
If applicants choose to include a clinical trial, plans should align with NIH expectations for rigorous study design, appropriate outcome measures, and protections for human subjects, while remaining consistent with the project’s commercialization goals.
What qualities does NIH emphasize for solutions addressing disparities?
The opportunity highlights that solutions should be effective, affordable, and culturally acceptable. Applicants are expected to consider real-world adoption issues that commonly affect disparity-focused innovations.
What real-world adoption issues should applicants consider based on the opportunity description?
The description highlights practical considerations such as usability, trust, language access, fit within workflows (including in low-resource clinics), and the practical costs of implementation and maintenance. Projects are more competitive when they clearly address these deployment realities.
What funding mechanism is used for this opportunity?
This opportunity uses the SBIR mechanism under NIH, specifically the R43/R44 grant structure intended to support small businesses from early feasibility through later-stage development with commercialization in mind.
Which federal agency administers this opportunity?
The opportunity is administered by the National Institutes of Health (NIH).
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number provided is RFA-MD-18-009.
What is the CFDA number listed for this opportunity?
The CFDA number listed in the provided information is 93.307.
What is the funding category and grant type indicated in the provided data?
Based on the provided source data, it is a discretionary grant opportunity under the health funding category.
When was this opportunity created and when did it close (based on the provided record)?
The provided record shows a creation date of 2018-08-01 and an original closing date of 2018-10-01, indicating it was released in 2018 as a time-limited solicitation.
Does the provided information include an award ceiling or expected number of awards?
No. The excerpt does not specify an award ceiling or the expected number of awards. Those details would typically be found in the full Funding Opportunity Announcement (FOA) text.
What would a strong application generally include, based on the description provided?
Based on the description, strong applications typically combine: (1) a clear disparity-focused public health need, (2) a practical innovation that can work in real settings at reasonable cost, (3) attention to cultural and community fit, and (4) a credible commercialization strategy showing how the innovation will reach the populations who need it.
Browse more opportunities from the same category: Health
Next opportunity: Engage youth to research, connect and interpret stories of suffrage
Previous opportunity: Advancing mAbs to Achieve a Drug-free Sustained HIV Virologic Remission (U01 Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA MD 18 009
Applicants also applied for:
Applicants who have applied for this opportunity (RFA MD 18 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| Management of Asthma in Primary Care - Clinical Center (UG3/UH3 - Clinical Trial Required) Apply for RFA HL 19 005 Funding Number: RFA HL 19 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Management of Asthma in Primary Care - Bioinformatics Center (U24 - Clinical Trial Required - Infrastructure) Apply for RFA HL 19 006 Funding Number: RFA HL 19 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alzheimer Centers for Discovery of New Medicines (U54 Clinical Trial Not Allowed) Apply for RFA AG 19 010 Funding Number: RFA AG 19 010 Agency: National Institutes of Health Category: Health Funding Amount: $5,250,000 |
| 2019 YSEALI Regional Workshop: Partnership in Health – Community-based Prevention for Non-communicable Diseases and Mental Health Apply for PAS ID 18 003 Funding Number: PAS ID 18 003 Agency: U.S. Mission to Indonesia Category: Health Funding Amount: $250,000 |
| Limited Competition: Renewal of, and Revisions to, the Alzheimer's Disease Genetics Consortium (U01 Clinical Trial Not Allowed) Apply for PAR 18 889 Funding Number: PAR 18 889 Agency: National Institutes of Health Category: Health Funding Amount: $2,500,000 |
| Limited Competition: Additional Sequencing for the Alzheimer's Disease Sequencing Project: Opportunity for Revision Requests for Active Cooperative Agreements (U01 Clinical Trial Not Allowed) Apply for PAR 18 890 Funding Number: PAR 18 890 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Neuroprotection (U01 Clinical Trial Not Allowed) Apply for RFA NS 18 033 Funding Number: RFA NS 18 033 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Advancing Extracellular RNA (exRNA) Communication Research: Improved Isolation and Analysis of exRNA-Carrier Subclasses (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 18 027 Funding Number: RFA RM 18 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited competition: Data Management and Resource Repository (DMRR) on Extracellular RNA (U54 Clinical Trial Not Allowed) Apply for RFA RM 18 026 Funding Number: RFA RM 18 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Neuroprotection - Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA NS 18 034 Funding Number: RFA NS 18 034 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Advancing Extracellular RNA (exRNA) Communication Research: Towards Single Extracellular Vesicle (EV) Sorting, Isolation, and Analysis of Cargo (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA RM 18 028 Funding Number: RFA RM 18 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIMHD Minority Health and Health Disparities Research Training (MHRT) Program (T37) Apply for RFA MD 18 007 Funding Number: RFA MD 18 007 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36 Independent Clinical Trial Not Allowed) Apply for PAR 18 894 Funding Number: PAR 18 894 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| CNS-Targeted Drug Delivery Strategies for HIV (R01 Clinical Trial Not Allowed) Apply for PAR 18 895 Funding Number: PAR 18 895 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Trial on Effects of Statins in Older Adults without Clinical Cardiovascular Disease (U19 Clinical Trial Required) Apply for RFA AG 19 020 Funding Number: RFA AG 19 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional) Apply for RFA MH 19 240 Funding Number: RFA MH 19 240 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Skin and Rheumatic Diseases (X02 Clinical Trial Not Allowed) Apply for PAR 18 899 Funding Number: PAR 18 899 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Innovative Adaptations to Simplify Existing Technologies for Manipulation and Analysis of Glycans (U01 Clinical Trial Not Allowed) Apply for RFA RM 18 037 Funding Number: RFA RM 18 037 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Pre-Application: Research Innovation for Scientific Knowledge (RISK) for Musculoskeletal Diseases (X02 Clinical Trial Not Allowed) Apply for PAR 18 900 Funding Number: PAR 18 900 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01 - No Clinical Trial Allowed) Apply for RFA CA 19 004 Funding Number: RFA CA 19 004 Agency: National Institutes of Health Category: Health Funding Amount: $499,999 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA MD 18 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.